A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection

Abstract

Infections with dengue virus (DENV) and Zika virus (ZIKV) can induce cross-reactive antibody responses. Two immunodominant epitopes—one to precursor membrane protein and one to the fusion loop epitope on envelope (E) protein—are recognized by cross-reactive antibodies1,2,3 that are not only poorly neutralizing, but can also promote increased viral replication and disease severity via Fcγ receptor-mediated infection of myeloid cells—a process termed antibody-dependent enhancement (ADE)1,4,5. ADE is a significant concern for both ZIKV and DENV vaccines as the induction of poorly neutralizing cross-reactive antibodies may prime an individual for ADE on natural infection. In this report, we describe the design and production of covalently stabilized ZIKV E dimers, which lack precursor membrane protein and do not expose the immunodominant fusion loop epitope. Immunization of mice with ZIKV E dimers induces dimer-specific antibodies, which protect against ZIKV challenge during pregnancy. Importantly, the ZIKV E-dimer-induced response does not cross-react with DENV or induce ADE of DENV infection.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Engineering, production and assessment of ZIKV E-monomer and E-dimer proteins.
Fig. 2: Binding properties of mice sera following immunization with ZIKV E-monomer and E-dimer proteins.
Fig. 3: Neutralizing and ADE activities of mouse sera following immunization with the ZIKV E-monomer and E-dimer proteins.
Fig. 4: In-depth characterization of the immune response to ZIKV E monomers and E dimers.
Fig. 5: The E-dimer vaccine protects against ZIKV infection in C57BL/6 mice.

Data availability

The authors declare that the data and materials supporting the findings of this study are available within the paper and its Supplementary Information files, or can be obtained on request from the corresponding authors.

References

  1. 1.

    Dejnirattisai, W. et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745–748 (2010).

  2. 2.

    Beltramello, M. et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8, 271–283 (2010).

  3. 3.

    Stiasny, K., Kiermayr, S., Holzmann, H. & Heinz, F. X. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol. 80, 9557–9568 (2006).

  4. 4.

    Dejnirattisai, W. et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16, 170–177 (2015).

  5. 5.

    Halstead, S. B. & O’Rourke, E. J. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265, 739–741 (1977).

  6. 6.

    Musso, D. & Gubler, D. J. Zika virus. Clinical Microbiol. Rev. 29, 487–524 (2016).

  7. 7.

    Cao-Lormeau, V. M. et al. Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387, 1531–1539 (2016).

  8. 8.

    Brasil, P. et al. Zika virus outbreak in Rio de Janeiro, Brazil: clinical characterization, epidemiological and virological aspects. PLoS Negl. Trop. Dis. 10, e0004636 (2016).

  9. 9.

    Miner, J. J. et al. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell 165, 1081–1091 (2016).

  10. 10.

    Diamond, M. S., Ledgerwood, J. E. & Pierson, T. C. Zika virus vaccine development: progress in the face of new challenges. Annu. Rev. Med. 70, 121–135 (2019).

  11. 11.

    Crill, W. D. & Chang, G. J. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 78, 13975–13986 (2004).

  12. 12.

    Dejnirattisai, W. et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat. Immunol. 17, 1102–1108 (2016).

  13. 13.

    Barba-Spaeth, G. et al. Structural basis of potent Zika–dengue virus antibody cross-neutralization. Nature 536, 48–53 (2016).

  14. 14.

    Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823–826 (2016).

  15. 15.

    Bardina, S. V. et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science 356, 175–180 (2017).

  16. 16.

    Brown, J. A. et al. Dengue virus immunity increases Zika virus-induced damage during pregnancy. Immunity 50, 751–762 (2019).

  17. 17.

    McCracken, M. K. et al. Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques. PLoS Pathog. 13, e1006487 (2017).

  18. 18.

    George, J. et al. Prior exposure to Zika virus significantly enhances peak dengue-2 viremia in rhesus macaques. Sci. Rep. 7, 10498 (2017).

  19. 19.

    Pantoja, P. et al. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat. Commun. 8, 15674 (2017).

  20. 20.

    Gordon, A. et al. Prior dengue virus infection and risk of Zika: a pediatric cohort in Nicaragua. PLoS Med. 16, e1002726 (2019).

  21. 21.

    Rodriguez-Barraquer, I. et al. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science 363, 607–610 (2019).

  22. 22.

    Rey, F. A., Stiasny, K., Vaney, M. C., Dellarole, M. & Heinz, F. X. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Rep. 19, 206–224 (2018).

  23. 23.

    De Alwis, R. et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl Acad. Sci. USA 109, 7439–7444 (2012).

  24. 24.

    Zhao, H. et al. Structural basis of Zika virus-specific antibody protection. Cell 166, 1016–1027 (2016).

  25. 25.

    Rouvinski, A. et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520, 109–113 (2015).

  26. 26.

    Abbink, P. et al. Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. Nat. Med. 24, 721–723 (2018).

  27. 27.

    Fernandez, E. et al. Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. Nat. Immunol. 18, 1261–1269 (2017).

  28. 28.

    Teoh, E. P. et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci. Transl. Med. 4, 139ra183 (2012).

  29. 29.

    Fibriansah, G. et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat. Commun. 6, 6341 (2015).

  30. 30.

    Hasan, S. S. et al. A human antibody against Zika virus crosslinks the E protein to prevent infection. Nat. Commun. 8, 14722 (2017).

  31. 31.

    Fibriansah, G. et al. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 349, 88–91 (2015).

  32. 32.

    Long, F. et al. Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope. Proc. Natl Acad. Sci. USA 116, 1591–1596 (2019).

  33. 33.

    Wang, J. et al. A human bi-specific antibody against Zika virus with high therapeutic potential. Cell 171, 229–241 (2017).

  34. 34.

    Bailey, M. J. et al. Human monoclonal antibodies potently neutralize Zika virus and select for escape mutations on the lateral ridge of the envelope protein. J. Virol. 93, e00405–e00419 (2019).

  35. 35.

    Rouvinski, A. et al. Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. Nat. Commun. 8, 15411 (2017).

  36. 36.

    Slon Campos, J. L. et al. Temperature-dependent folding allows stable dimerization of secretory and virus-associated E proteins of dengue and Zika viruses in mammalian cells. Sci. Rep. 7, 966 (2017).

  37. 37.

    Pierson, T. C. et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1, 135–145 (2007).

  38. 38.

    Oliphant, T. et al. Induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 81, 11828–11839 (2007).

  39. 39.

    Collins, M. H. et al. Lack of durable cross-neutralizing antibodies against Zika virus from dengue virus infection. Emerg. Infect. Dis. 23, 773–781 (2017).

  40. 40.

    Robbiani, D. F. et al. Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico. Cell 169, 597–609 (2017).

  41. 41.

    Sheehan, K. C. et al. Blocking monoclonal antibodies specific for mouse IFN-α/β receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J. Interferon Cytokine Res. 26, 804–819 (2006).

  42. 42.

    Sapparapu, G. et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540, 443–447 (2016).

  43. 43.

    Gorman, M. J., Poddar, S., Farzan, M. & Diamond, M. S. The interferon-stimulated gene Ifitm3 restricts West Nile virus infection and pathogenesis. J. Virol. 90, 8212–8225 (2016).

  44. 44.

    Frierson, J. G. The yellow fever vaccine: a history. Yale J. Biol. Med. 83, 77–85 (2010).

  45. 45.

    Collins, M. H. & Metz, S. W. Progress and works in progress: update on flavivirus vaccine development. Clin. Ther. 39, 1519–1536 (2017).

  46. 46.

    Flipse, J. & Smit, J. M. The complexity of a dengue vaccine: a review of the human antibody response. PLoS Negl. Trop. Dis. 9, e0003749 (2015).

  47. 47.

    Keasey, S. L. et al. Antibody responses to Zika virus infections in environments of flavivirus endemicity. Clin. Vaccine Immunol. 24, e00036-17 (2017).

  48. 48.

    Langerak, T. et al. The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis. PLoS Pathog. 15, e1007640 (2019).

  49. 49.

    Richner, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168, 1114–1125 (2017).

  50. 50.

    Petris, G., Bestagno, M., Arnoldi, F. & Burrone, O. R. New tags for recombinant protein detection and O-glycosylation reporters. PLoS ONE 9, e96700 (2014).

  51. 51.

    Gorman, M. J. et al. An immunocompetent mouse model of Zika virus infection. Cell Host Microbe 23, 672–685 (2018).

  52. 52.

    Lopez-Camacho, C. et al. Assessment of immunogenicity and neutralisation efficacy of viral-vectored vaccines against chikungunya virus. Viruses 11, E322 (2019).

  53. 53.

    Lazear, H. M. et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe 19, 720–730 (2016).

Download references

Acknowledgements

This work was supported by the Wellcome Trust (collaborative grant 203224/Z/16/Z to G.R.S. and J.M.), National Institute for Health Research Biomedical Research Centre Funding Scheme (to G.R.S.), Medical Research Council Newton fund (UK–Thailand joint initiative of infectious diseases grant MR/R020957/1 to J.M.), National Institutes of Health (grants R01 AI073755, R01 AI127828 and R01 HD091218 to M.S.D., and grant T32 AI007172 to B.W.J.), UK Department of Health and Social Care (projects 972216 and 971557 to A.R.-S.) and French Government’s Programme d’Investissements d’Avenir (Labex Integrative Biology of Emerging Infectious Diseases grant ANR-10-LABX-62-IBEID 4E AAP to F.A.R.). G.R.S. is supported as a Wellcome Trust Senior Investigator (grant 095541/A/11/Z). We thank Y. C. Kim and B. D. Jimenez for technical assistance.

Author information

G.R.S., J.M. and F.A.R. conceived the study. G.R.S., J.M., F.A.R., M.S.D., A.R.-S., J.L.S.-C., W.D., B.W.J., L.A.D., E.S.W., R.E.C. and C.L.-C. designed the experiments and analyzed the data. J.L.S.-C., W.D., B.W.J., C.L.-C. and W.W. performed the experiments. G.R.S. wrote the paper, with editorial input from all co-authors.

Correspondence to Juthathip Mongkolsapaya or Gavin R. Screaton.

Ethics declarations

Competing interests

G.R.S., F.A.R. and J.M. are named inventors on a patent owned by Imperial College London and Institut Pasteur describing the EDE and its use as a potential immunogen (application number EP3172229A1). G.R.S. sits on the advisory board of GSK Vaccines. M.S.D. is a consultant for Inbios and Atreca, and sits on the Scientific Advisory Board at Moderna. The remaining authors declare no competing interests.

Additional information

Peer review information: Jamie Wilson was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Integrated supplementary information

Supplementary Figure 1 Binding, neutralizing and ADE activities of outbred CD1 mouse sera following immunization with ZIKV E-monomer and E-dimer proteins.

Three groups of female CD1 mice (n=6 animals per group) were immunized with E-dimer, E-monomer, or CHIKV E2 as before, using Addavax as adjuvant. (a) ELISA analysis showing the antibody titres obtained from ZIKV E-monomer (left panel), ZIKV E-dimer (middle panel) and CHIKV E2 (right panel), immunized-mouse serum on captured ZIKV and DENV 1-4 virions (for each virus, n=6 individual mouse serum per group). (b) FRNT50 titres against ZIKV and DENV 1-4 were calculated for animals immunized with ZIKV E-monomer (left panel), ZIKV E-dimer (middle panel) and CHIVK E2 (right panel) (for each virus, n=6 individual mouse serum per group); in (a-b) individual measurements, as well as arithmetic mean±s.d. values are shown. (c-d) Infection enhancement curves (FFU/ml) of U937 cells infected with ZIKV PF13 (c) and DENV-2 16681 (d) viruses in presence of serially-diluted mouse immune serum (n=6 individual mouse serum per group). The data are shown as single data points and arithmetic mean.

Supplementary Figure 2 Depletion of specific antibody populations from mouse immune sera.

Serum was collected from BALB/c mice 10 weeks post prime, pooled by group and incubated with a series of antigen-displaying yeast to remove specific fractions of antibodies. The depleted sera were tested by flow cytometry for any remaining reactivity and additional rounds of depletion were performed until all the antigen-specific activity was removed. Flow cytometry profiles showing the reactivity of each sera before (red) and after (blue) depletion with each antigen displaying-yeast are shown; histogram plots were used to facilitated comparison and a negative control using mock yeast (black) was added to demonstrate complete depletion of antibody. The data shown is representative of three independent experiments performed for each depletion and sera.

Supplementary Figure 3 Profiles and in-depth characterization of the immune response to ZIKV E-monomers and E-dimers using alum as adjuvant.

Three groups of female BALB/C mice (n=6 animals per group) were immunized with E-dimer, E-monomer, or CHIKV E2, Alum was use as adjuvant throughout. (a) ELISA analysis showing the antibody titres of mouse immune serum to captured ZIKV PF13 virions (left) and ZIKV E-dimers (right) (n=6 individual mouse serum for each group and time point); single data points and arithmetic mean (solid lines) are shown. (b) FRNT50 (left) and FRNT90 (right) titres against ZIKV were calculated for individual animals in each group (n=6 individual mouse serum for each group). The dashed lines indicate the limit of detection of the assay. Individual measurements, as well as geometric mean±s.d. values are noted. (c) ELISA analysis showing the antibody titres of ZIKV E-monomer- (left panel), ZIKV E-dimer- (middle panel) and CHIKV E2- (right panel) immune mouse serum to captured DENV 1-4 virions (for each virus, n=6 individual mouse serum per group). (d) FRNT50 titres against DENV 1-4 were also calculated (for each virus, n=6 individual mouse serum per group); in (b-d) individual measurements, as well as arithmetic mean±s.d. values are shown. (e-f) Infection enhancement curves (FFU/ml) of U937 cells infected with ZIKV PF13 (e) and DENV-2 16681 (f) viruses in presence of mouse immune serum (for each virus, n=6 individual mouse serum per group). The data are shown as single data points and arithmetic mean (solid lines). (g-k) Flow cytometry profiles of E-monomer and E-dimer mouse immune serum against yeast displaying ZIKV ED3 (g), ED12 (h), ED123 (i) and ED12 carrying the W101A mutation (j) as well as DENV-2 ED12 (k); in all cases, n=6 individual mouse serum for each group. Data is presented as individual measurements and arithmetic mean (solid lines). In (j), profiles obtained with the wild type ZIKV ED12 were included for comparison (dashed lines). (l) Serum was depleted of specific antibodies using antigen-displaying yeasts and analyzed for ZIKV neutralization activity, FRNT50 titres were calculated (for each group, n=2 independent depletion experiments using pooled sera). The data is presented as floating bars showing mean (central line), maximum and minimal values together with individual measurements for each group and depletion.. (m) Infection enhancement curves (FFU/ml) of U937 cells infected with DENV-2 16681 in presence E-monomer immune mouse serum after depletion of specific antibodies as in l (for each depletion, n=2 independent experiments using depleted-pooled). Data are shown as single data points and arithmetic mean.

Supplementary Figure 4 ZIKV-neutralizing activities of WT C57BI/6J mice immunized with ZIKV E-monomer and E-dimer proteins.

WT C57BI/6J were immunized and boosted with ZIKV E-monomer, ZIKV E-dimer or CHIKV E2 proteins using Addavax as adjuvant. Neutralizing potential of the serum was determined by FRNTs and individual mouse neutralization curves are shown. n=25 animals per group. Each point represents the mean of two technical replicates with error bars denoting the range, each graph shows the results of 5 individual animals.

Supplementary information

Supplementary Information

Supplementary Figs. 1–4

Reporting Summary

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading